Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

[1]  V. Torri,et al.  Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial , 2020, ESMO Open.

[2]  V. Torri,et al.  Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. , 2020, Clinical colorectal cancer.

[3]  Y. Bang,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.

[4]  F. Ciardiello,et al.  Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. , 2020, JAMA oncology.

[5]  P. Jänne,et al.  Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. , 2020, Cancer discovery.

[6]  Jing-Yuan Fang,et al.  Comprehensive review of targeted therapy for colorectal cancer. , 2020, Signal transduction and targeted therapy.

[7]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Nakagawa,et al.  [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification , 2019, International journal of cancer.

[9]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[10]  N. Kemeny,et al.  Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial , 2019, Annals of Oncology.

[11]  Yusuke Nakamura,et al.  TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study , 2019, Annals of Oncology.

[12]  V. Torri,et al.  HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. , 2019, The oncologist.

[13]  H. Iwata,et al.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.

[14]  C. Redfern,et al.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.

[15]  J. Hainsworth,et al.  Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. , 2019, The Lancet. Oncology.

[16]  Jeffrey S. Morris,et al.  Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. , 2019, JCO precision oncology.

[17]  A. Bardelli,et al.  Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.

[18]  T. Yamanaka,et al.  Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer , 2018, Clinical colorectal cancer.

[19]  A. Bardelli,et al.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  James X. Sun,et al.  Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 , 2018, Cancer.

[21]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Kitano,et al.  Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. , 2017, The Lancet. Oncology.

[23]  S. Kubicka,et al.  Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. , 2017, Cancer treatment reviews.

[24]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. Agatsuma,et al.  Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.

[26]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[27]  L. Sánchez-Lorenzo,et al.  Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It , 2016, Clinical Medicine Insights. Oncology.

[28]  Marc Peeters,et al.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.

[29]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[30]  G. Sauter,et al.  Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. , 2010, Human pathology.